OTC NSAIDs Need Additional Label Warnings – FDA Advisory Panel
This article was originally published in The Tan Sheet
Executive Summary
Labels for OTC NSAIDS need additional information about potential risks, say panel members in a joint meeting of the Arthritis and the Drug Safety and Risk Management advisory committees. Data do not show naproxen has a lower CV thrombotic event risk compared to other NSAIDs, they say.